Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $62.78.

Several research firms have recently weighed in on HALO. Benchmark reissued a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company reduced their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th.

Halozyme Therapeutics Trading Up 1.9 %

Shares of Halozyme Therapeutics stock traded up $1.15 during midday trading on Friday, reaching $63.02. The company had a trading volume of 1,571,854 shares, compared to its average volume of 1,383,175. The firm has a market cap of $7.79 billion, a PE ratio of 18.37, a P/E/G ratio of 0.42 and a beta of 1.32. The stock has a fifty day moving average price of $59.62 and a 200 day moving average price of $54.90. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics has a fifty-two week low of $37.73 and a fifty-two week high of $66.00.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. On average, equities analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,200 shares of company stock valued at $1,786,668. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new stake in Halozyme Therapeutics during the fourth quarter worth $60,054,000. Capital World Investors purchased a new position in shares of Halozyme Therapeutics in the 4th quarter worth about $35,773,000. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after buying an additional 581,475 shares during the period. D. E. Shaw & Co. Inc. increased its holdings in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock worth $39,750,000 after buying an additional 524,802 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Halozyme Therapeutics during the fourth quarter worth about $21,838,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.